Mazdutide

Approved in China · Innovent / Eli Lilly. The world's first approved GLP-1/glucagon drug, licensed in China. Not available in the US or Europe.

Average weight loss

14.8%

Stopped for side effects

n/r

Trial length

48 wk

Ranking score

n/r

GLORY-1 results

Phase 3 · 48 weeks · 6 mg weekly
Chinese adults with obesity or overweight (n=610)

Weight loss

14.8%

Nausea

n/r

Vomiting

n/r

Diarrhea

n/r

Constipation

n/r

Quit due to side effects

n/r

n/r = not reported. Counting everyone who started, weight loss was 14%. Placebo group: 0.5%.

Trial population had a lower starting weight than Western trials, which limits comparison.

–

Not yet ranked

Side-effect data incomplete. We rank only drugs with a completed Phase 3 trial and published side-effect rates.